Eli M. Wallace - 02 Oct 2025 Form 4 Insider Report for BridgeBio Oncology Therapeutics, Inc. (HLXB)

Role: Chief Executive Officer, Director
Signature: /s/ Aaron Chan, Attorney-in-Fact
Issuer symbol: HLXB
Transactions as of: 02 Oct 2025
Net transactions value: $0
Form type: 4
Filing time: 06 Oct 2025, 16:22:15 UTC
Previous filing: 28 Aug 2025
Next filing: 12 Dec 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Wallace Eli M.	Chief Executive Officer, Director	BRIDGEBIO ONCOLOGY THERAPEUTICS, INC., 256 EAST GRAND AVENUE, SUITE 104, SOUTH SAN FRANCISCO	/s/ Aaron Chan, Attorney-in-Fact	06 Oct 2025	0001776352

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BBOT	Stock Option (Right to Buy)	Award	$0	+1,614,400		$0.000000	1,614,400	02 Oct 2025	Common Stock	1,614,400	$12.44	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of October 2, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date.